Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · August 22, 2022

Real-World Safety and Efficacy of Pembrolizumab in Japanese Patients With Radically Unresectable Melanoma

The Journal of Dermatology


Additional Info

The Journal of Dermatology
Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan
J Dermatol 2022 Jul 27;[EPub Ahead of Print], N Yamazaki, A Shimizu, M Ozaki, M Hamada, N Takeuchi, Y Ito, S Maekawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading